FLAURA2 Postprogression Outcomes
FLAURA2: Postprogression Outcomes of First-line Osimertinib ± Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC

Released: May 03, 2024

Expiration: May 02, 2025

Activity

Progress
1
Course Completed